Modern Asset Lab

No usable evidence was supplied for a commercial entity named Modern Asset Lab. The only source provided (E1) is a press release about Debiopharm, a privately owned Swiss biopharmaceutical company, and its MultiLINK antibody-drug-conjugate linker technology presented at World ADC San Diego 2026. That article contains no mention of Modern Asset Lab, no product, company, platform, ownership, headquarters, or market information connected to that name. Because the identity of the subject cannot be established from the evidence, this entry is intentionally kept short and flagged for review rather than filled with speculative or invented details. If Modern Asset Lab is a real brand, additional primary sources such as an official website, corporate registry filing, or press coverage would be required to write a reliable dossier.

• 2026-10-14

  Modern Asset Lab launches Match Protocol™ AEO/GEO framework alongside benchmark of 100 U.S. small businesses[2]Modern Asset Lab 推出 Match Protocol™ AEO/GEO 框架并发布针对100家美国小企业的基准测试prnewswire.com

  Reported: 2026-10-14

  On Oct. 14, 2026, Modern Asset Lab launched Match Protocol™, a proprietary five-layer framework for Answer Engine Optimization (AEO) and Generative Engine Optimization (GEO), together with the Match Protocol Score™ available at match.modernassetlab.com. In the accompanying Match Protocol™ Benchmark, 100 U.S. small businesses across 10 industries and 11 metro areas were run through up to 32 blind buyer conversations with ChatGPT, Google AI Overviews, Perplexity and Gemini; the company reported that 80 of the 100 landed in the bottom 'Ghosted' tier, with an average score of 50.9 of 100.

1. 1Debiopharm's Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistancefinanznachrichten.de
2. 2Modern Asset Lab 推出 Match Protocol™ AEO/GEO 框架并发布针对100家美国小企业的基准测试prnewswire.com